Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Mapping lung cancer genes to unlock future treatments

NCT ID NCT02688894

Knowledge-focused Sponsor: Samsung Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Aug 13, 2026 · Updated 3 times

Summary

This study analyzes tumor tissue from 797 people with relapsed small cell lung cancer to identify genetic subtypes. No drugs are tested here. Instead, the results may help match patients to future targeted therapy trials. Participants must have had prior platinum-based chemotherapy and provide tissue samples.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this screening could identify which genetic subtypes of small cell lung cancer exist, paving the way for more personalized treatment trials.
What could go wrong
This is only a screening study, not a treatment. It does not test any drug, so there is no direct benefit to participants. Results may not lead to effective therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 797 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2016

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Histologically or cytologically confirmed Small cell lung cancers

Ages

20 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Provision of fully informed consent prior to any study specific procedures. 2. Patients must be ≥20 years of age. 3. Histologically or cytologically confirmed Small cell lung cancers 4. ECOG performance status of 0 to 2 5. Patients who are being treated or were treated with platinum-based chemotherapy as a first-line treatment 6. Patients with available archival tissues for molecular analysis or patients who agreed with biopsy for molecular analysis Exclusion Criteria: 1. More than two prior chemotherapy regimen for the treatment of small cell lung cancer 2. Pregnant or nursing women (women of reproductive potential have to agree to use an effective contraceptive method) 3. Patients with second primary cancer, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for ≤2 years.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neuroendocrine; carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

neuroendocrine carcinoma small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Neuroendocrine; carcinoma Small cell lung cancers

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chungbuk University Hospital

    COMPLETED

    Taebuk, South Korea

  • Gachon University Gil Medical Center

    COMPLETED

    Incheon, South Korea

  • Samsung Medical Center

    RECRUITING

    Seoul, 135-710, South Korea

  • Seoul National University Bundang Hospital

    COMPLETED

    Seongnam, South Korea

  • Ulsan University Hospital

    COMPLETED

    Ulsan, South Korea

  • VHS Medical Center

    COMPLETED

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.